-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2024-510913-13-00
10
2018-05-18
Previously Untreated Metastatic or Unresectable Melanoma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-513521-23-00
5
2015-08-19
Prostate Cancer
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-519278-37-00
4
2025-10-22
Lupus Nephritis
-
2024-518841-12-00
9
2025-03-25
HER2 positive resectable esophagogastric adenocarcinoma
-
2023-508812-45-00
10
2024-11-11
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
-
2024-511998-30-00
5
2024-10-18
Narcolepsy with Cataplexy (Narcolepsy Type 1)
-
2023-507376-50-00
1
2024-09-27
Ulcerative Colitis
-
2023-508679-34-00
4
2024-07-30
Ulcerative Colitis
-
2023-508209-25-00
1
2024-04-19
B-Cell Non-Hodgkin’s Lymphoma (B-NHL)
-
2023-505257-40-00
9
2024-04-17
metastatic esophagogastric adenocarcinoma (Stage IV)
-
2023-503693-20-01
5
2024-04-10
Severe eosinophilic asthma
-
2022-502540-12-00
5
2023-11-09
Refractory Status Epilepticus (RSE)
-
2023-503830-27-00
4
2023-10-17
Large B-Cell Lymphoma (LBCL)
-
2023-503251-10-00
4
2023-10-10
Metastatic Breast Cancer or Advanced Non-Small Cell Lung Cancer with a
-
2022-502393-16-00
5
2023-09-06
Moderately to Severely Active Ulcerative Colitis
-
2023-504281-34-00
3
2023-08-22
Adult patients with advanced solid tumors
-
2022-501417-31-01
5
2023-08-01
melanoma